title: The paraoxonase-2-310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus.
abstract: OBJECTIVE
  To investigate the paraoxonase-2 (PON 2)-C/S 310 polymorphism and its relationship to the presence of diabetic complications and glycaemic control.
  
  
  METHODS
  Case-control study.
  
  
  METHODS
  One study centre at University hospital.
  
  
  METHODS
  The subjects were people with type 2 diabetes (n=252), type 1 diabetes (n=152) and healthy controls (n=282). The PON 2-C/S 310 polymorphism was measured by restriction fragment length polymorphism analysis. Lipids and lipoproteins were measured by standard clinical chemistry methods. Diabetes and diabetic complications were defined by World Health Organization criteria.
  
  
  RESULTS
  There was an over-representation of the C/C 310 genotype in those with diabetes and microvascular complications (type 2 diabetes P=0.043, type 1 diabetes P=0.052, both populations combined P=0.014). The PON 2-C/S 310 polymorphism was also associated with glycaemic control. C 310/C 310 homozygotes had the highest HbA(1c) concentration (P=0.020 type 2 diabetes, P=0.065 type 1 diabetes, P=0.035 both populations combined). There was no association between the PON 2-310 polymorphism and lipid and lipoprotein concentrations.
  
  
  CONCLUSIONS
  PON 2 could be directly involved in protecting critical enzymes or organelles against oxidative damage; PON2 may thus predispose to the development of microvascular complications.
authors.affiliation: University Department of Medicine, Manchester Royal Infirmary, Manchester, UK.
authors.forename: B
authors.initials: B
authors.lastname: Mackness
authors.forename: P
authors.initials: P
authors.lastname: McElduff
authors.forename: M I
authors.initials: MI
authors.lastname: Mackness
mesh_terms: D000328:Adult; D043303:Aryldialkylphosphatase / Q000235:genetics*; D001786:Blood Glucose / Q000032:analysis; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications* / Q000201:enzymology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000201:enzymology; D003925:Diabetic Angiopathies / Q000097:blood / Q000201:enzymology*; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006720:Homozygote; D006801:Humans; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic
chemical_list: D001786:Blood Glucose; D008055:Lipids; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D043303:Aryldialkylphosphatase; C468411:PON2 protein, human